CP-316819

CP-316819 (GPi 819) is a blood-brain barrier permeable glycogen phosphorylase inhibitor. CP-316819 inhibits hepatic glycogenolysis, safely reduces blood glucose in type 2 diabetes, and rarely induces hypoglycemia. CP-316819 increases brain glycogen reserves, protects neurons, alleviates hypoglycemic brain injury, and inhibits excessive platelet activation, exerting both neuroprotective and vasculoprotective effects. CP-316819 can be used in research related to hypoglycemia, thrombosis, autoimmune inflammatory diseases, and type 2 diabetes^[1][2][3][4]. In Vitro:CP-316819 (50 μM; 0-20 minutes) transiently inhibits the early α-granule exocytosis of thrombin-stimulated control mouse platelets, and exocytosis returns to normal at 20 minutes after stimulation^[2].
CP-316819 (0-1 mM; 24 h) increases glycogen content in primary Swiss-Webster mouse forebrain astrocyte cultures in a dose-dependent manner, without preventing glycogen utilization during glucose deprivation^[3]. In Vivo:CP-316819 (2.5-10.0 mg/24 h; intracerebroventricular administration; continuous infusion; 24 h) causes a dose-dependent increase in hypothalamic glycogen content in male Sprague-Dawley rats^[1].
CP-316819 (initial dose of 150 mg/kg, followed by 50 mg/kg at 12 h and 16 h after the initial administration; intraperitoneal injection) increases brain glycogen content in rats and prolongs the duration of neuronal activity under hypoglycemic conditions^[3].